• 金彩汇

    shouji-banner750X600
    long-acting interferon drug product company in Hepatitis and Cytokines

    Welcome To Amoytop Biotech

    Xiamen Amoytop Biotech Co., Ltd. is an innovative biopharmaceutical company and a listed company on the Science and Technology Innovation Board (SSE STAR Market) in China, specializing in R&D, manufacturing and marketing of regular and long-acting recombinant protein drugs. Focusing on the R&D of immune-related cytokine medicines, Amoytop Biotech is committed to becoming a leader in solving cytokine medicine-based systemic immune problems, providing better solutions for major diseases (such as viral hepatitis, malignant tumors) and immunotherapy. Looking into the future, Amoytop Biotech is especially focusing on CHB (chronic hepatitis B) treatment and will keep advancing the clinical research progress of multiple ongoing pipeline programs aiming to achieve breakthroughs in the clinical cure of CHB.

    Research and Innovation

    Amoytop Biotech is a leading biopharmaceutical company in China, specialized in R&D and production of recombinant protein drugs, and committed to providing better solutions for viral hepatitis, malignant tumor and immunotherapy etc..
    • According to company's development strategy, basing on the characteristics, life cycle management and trends...
    • Insisting on constant innovation and development, Amoytop Biotech has created research...​​​​​​​
    • Focusing on major disease treatment and aiming to provide better innovative protein drugs...
    • After over 20 years of innovation and development, Amoytop Biotech has owned many core technology platform...

    Specialized In R&D And Production Of Recombinant Protein Products

    Prodcut Center

    Stay Updated With Our Latest News

    网站封面新闻图.png
    Approval Granted for Amoytop Biotech's Pegpesen®, a Next-Gen Long-Acting Growth Hormone

    On May 29, Amoytop Biotech's independently developed Class 1 new drug, Inpegsomatropin Injection(trade name: Pegpesen®), the world's first Y-shaped 40-kDa PEGylated long-acting growth hormone, officially received market approval from the National Medical Products Administration (NMPA). This drug is

    网站封面新闻图.png
    AMOYTOP BIOTECH ANNOUNCES CLINICAL COLLABORATION WITH ALIGOS THERAPEUTICS INC

    Jul 22, 2024Xiamen, China, July 22, 2024/--Xiamen Amoytop Biotech Co., Ltd. (referred to as Amoytop hereinafter) today announced that it has entered into a clinical trial collaboration agreement with Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”).

    Contact Details

    Emal: international@goodwjj.com; reagent@goodwjj.com
    Tel: +86-592-6889106
    Hand phone: +86-18060918257
    Fax: +86-592-6889110
    Address: No. 330 Wengjiao Road, Xinyang Industry Zone of             Haicang, Xiamen, Fujian, P.R.China

    Get In Touch

    Get In Touch
    Facebook
    Twitter
    LinkedIn
    Instagram

    WELCOME

    Specialized in R&D and production of recombinant protein drugs, and committed to providing better solutions for viral hepatitis, malignant tumor and immunotherapy etc..
    Leave a Message
    Get In Touch